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We studied cytotoxic T lymphocyte (CTL) cross-reactivity between human immunodeficiency virus type 1 (HIV-1) subtypes
within a group of infants infected with either HIV-1 B or non-B clade. Fifteen children were infected with a clade B virus. Nine
were infected with non-B virus, including two clade A, four clade D, two clade F, and one clade G. CTL activities from in vitro
activated peripheral blood mononuclear cells were tested against autologous cell line infected with recombinant vaccinia
viruses encoding for Env, Gag, Pol, or Nef proteins from a clade A or B isolate. HIV-1-specific CTL elicited from infection with
clade B virus could lyse targets expressing clade A proteins, and vice versa. In infants with positive CTL responses,
cross-clade recognition was predominant and was detected within 88% of the Pol, 83% of the Nef, 67% of the Gag, and 55%
of the Env responders. Longitudinal studies showed that CTL cross-reactivity to both B and A targets was stable for several
years. Elicitation of CTL reactivities capable of elimination of virus-infected cells is an important goal for the development of
an efficient AIDS vaccine. The significant cross-reactivity of CTL shown in this study supports the concept that vac-
cines developed using a single-clade immunogen may be applicable to induce broadly reactive T cell responses. © 1998
Academic Press
INTRODUCTION
The functions of antigen-specific T lymphocytes are
required for recovery from viral infections, clearance of
virus, control of persistent infections, or a combination.
Cytotoxic T lymphocyte (CTL) activities specific to most
viral proteins have been detected in the peripheral blood
mononuclear cells (PBMCs) of human immunodeficiency
virus (HIV)-infected individuals (Johnson and Walker,
1994; Rivie`re et al., 1994, for review). Although HIV-spe-
cific CTL cannot fully clear the virus from infected hosts,
they appear to play a role in controlling disease progres-
sion (Greenough et al., 1997; Klein et al., 1995; Ogg et al.,
1998; Rivie`re et al., 1995). Virus-specific CTL are the first
virus-specific immune response detected, and they are
temporally associated with the reduction of viral load in
HIV-infected adults (Borrow et al., 1994; Koup et al., 1994;
Lamhamedi-Cherradi et al., 1995). In experimental mod-
els of viral infections, it has been demonstrated that
protective immunity after a viral challenge requires the
preexistence of memory virus-specific CTL (Fu et al.,
1997; Martins et al., 1995; Yokoyama et al., 1995). Thus
elicitation of CTL capable of control of viral replication
and elimination of virus-infected cells is an important
goal for the development of an efficient AIDS vaccine. In
view of the great sequence variability of HIV-1, a study of
the intensity of the cross-reactive immune responses
able to recognize the various HIV-1 strains is of particular
importance.
The different HIV-1 strains are classified into two
groups based on phylogenetic analysis with the use of
DNA sequences (Myers et al., 1996). The majority of the
sequences constitute the major (M) group of HIV-1 vi-
ruses, and a smaller number of sequences are classified
as O (outlier). The M group has been subdivided into 10
subtypes or clades (A–J) that differ from each another by
an average nucleotide percentage distance of 30%
based on env sequence. Subtype B is the most prevalent
subtype in the Caribbean, Europe, and North America.
The main geographic area is West, Central, and East
Africa for subtype A; India and East and South Africa for
subtype C; Central and East Africa for subtype D; East
Asia and Central Africa for subtype E; and South Amer-
ica, East Europe, and Central Africa for subtype F (Jans-
sens et al., 1997; Myers et al., 1996; Workshop Report
from the European Commission and UNAIDS, 1997).
The ability of infants, including newborns, to mount a
virus-specific cytotoxic response has been reported by
different investigators (Buseyne et al., 1993; Luzuriaga et
al., 1991, 1995; McFarland et al., 1994). We studied the
HIV-specific CTL activities in a cohort of children
(Buseyne et al., 1993). These children are part of the
French pediatric cohort of whom approximately one third
of infants are of African origin and thus may be infected
by a subtype different from clade B. These patients
present two important characteristics regarding their im-
mune responses: they were infected when their immune
1 To whom reprint requests should be addressed. Fax: 33–140-613–
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system was not fully mature, and the diversity of HIV-1
strains is much broader than that in most other risk
groups in Western countries. In this study, we typed the
virus strains infecting these infants and compared their
CTL responses against HIV proteins from two clades (B
and A). This is the first description of significant CTL
cross-reactivity between clade B and non-B viruses in
HIV-1-infected infants. These results support the concept
that vaccines developed using a single-clade immuno-
gen may be applicable to induce broadly reactive T cell
responses.
RESULTS
Genetic subtyping of HIV-1 isolates
The genetic classification of HIV-1 isolates from these
infected infants was determined by HMA in 20 cases and
by phylogenetic analysis in four cases (EM50, EM66,
EM95, and EM97) as described under Materials and
Methods. Fifteen children were infected with a clade B
virus and nine with a non-B virus (Table 1). The geo-
graphic origins of the 15 infants infected with a clade B
virus were Europe (nine), North Africa (two), sub-Saharan
Africa (one), Haiti (one), and Asia (two). Eight of the nine
infants infected with a non-B clade virus were from sub-
Saharan Africa, and one was from Europe (Romania). As
shown in Table 1, two clade A (EM7, EM59), four clade D
(EM17, EM79, EM95, EM97), two clade F (EM50, EM66),
and one clade G (EM103) viruses were characterized.
For two D strains (EM95, EM97) and the two F strains
(EM50, EM66), the phylogenetic tree based on the C2-V3
nucleotide alignment and including reference strains
was constructed with the Neighbor–Joining method.
Trees constructed with the Fitch–Margoliash method
and maximum parsimony gave similar branching pat-
terns.
CTL cross-reactivity among different HIV-1 clades
T cell lines were derived after in vitro activation of
peripheral blood mononuclear cells (PBMCs) as de-
scribed under Materials and Methods. We have previ-
ously shown that HIV-specific effectors induced by this
stimulation protocol were MHC class I restricted CD31,
CD81 T-lymphocytes (Buseyne et al., 1993). The 24 chil-
dren were tested for their CTL activities. HLA typing,
clinical stage, and age of the children are summarized in
Table 1. The percentage of infants with a positive CTL
TABLE 1
Description of the Patients Studied
Patient Agea Stageb
HLAc
Clade OriginA A B B C C
EM 42 7 A3 0205 23 35 45 4 6 B Europe
EM 45 7, 5 N2 2 0301 1401 39 0802 1203 B Europe
EM 47 9, 6 A2 30 68 53 53 4 4 B Europe
EM 48 7, 4 A3 11 24 35 49 0303 14 B Europe
EM 54 6 N1 2 24 27 39 0702 1203 B Europe
EM 60 5 B3 3004 6802 0704 5601 0302 0703 B Africa
EM 64 10, 6 N3 2 30 38 5801 0701 1203 B North Africa
EM 65 11, 1 A3 30 68 42 44 5 1701 B Haı¨ti
EM 68 12, 3 B2 11 32 50 56 2 9 B Europe
EM 75 12 A1 32 32 18 27 1 1203 B North Africa
EM 76 10 B1 2 2 1502 62v 9 0801 B Vietnam
EM 78 6, 4 B1 2 3 35 41 4 1701 B Europe
EM 84 7, 2 A1 33 6601 41 5801 10 1701 B Europe
EM 89 2 N2 2 24 35 44 4 5 B Europe
EM 96 12 A2 2 33 4801 58 8 10 B Cambodia
EM 07 3, 9 A3 30 68 8 65 0702 0702 A Zaire
EM 17 4, 1 B3 29 33 44 53 4 4 D Zaire
EM 50 10, 2 B3 2 29 13 45 6 1601 F Congo
EM 59 3, 9 C3 34 36 5301 5601 0302 1801 A Africa
EM 66 6, 5 A1 1 2 35 61 4 15 F Europe/Romania
EM 79 11, 5 A3 68 74 35 35 4 10 D Zaire
EM 95 3, 2 A1 30 68 8 62 4 0701 D Zaire
EM 97 8, 9 A2 34 68 13 62 1801 1801 D Zaire
EM 103 0, 7 N1 nd nd nd nd nd nd G Africa
Note. nd, not done.
a Age (years) at testing.
b Stage of the disease at testing.
c HLA genotypes.
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activity directed to Pol, Env, Gag, and Nef proteins was
77% (17/22), 39% (9/23), 38%(9/24), and 25% (6/24), re-
spectively (Table 2).
The CTL activities were classified as type specific
when a single clade (A or B) was recognized and cross-
reactive when both clades (A and B) were recognized.
Within the positive CTL responses, cross-reactivity was
found to be predominant: 15 of the 17 Pol responders
(88%), five of the six Nef responders (83%), six of the nine
Gag responders (67%), and five of nine Env responders
(55%) had CTL activities against both clade A and B
targets. Thus for the majority of HIV-1-infected infants
with positive CTL responses, there was a significant
cross-reactivity of CTL between clade B and non-B sub-
types for at least one of the four proteins tested.
Infants showing activities to both A and B targets were
infected with either a clade B or a non-B virus (Table 2):
HIV-1-specific CTL responses elicited from infection with
HIV-1 clade B (EM42, EM45, EM47, EM48, EM54, EM60,
EM64, EM68, EM76, and EM84) could cross-react with
targets expressing clade A protein, and HIV-1-specific
CTL responses elicited from infection with HIV-1 clade A,
D, or F (EM7, EM17, EM50, EM66, EM95, and EM97)
could cross-react with targets expressing clade B pro-
teins.
Longitudinal studies of CTL responses
For two infants infected with a non-B virus, a longitu-
dinal study was possible. As shown in Fig. 1, the Gag-
specific activity of infant EM7, infected with a subtype A
virus, was measured on five occasions from 2.3 to 9.3
years of age. The Gag-specific cytotoxic response was
found to be positive with a similar intensity to both A and
B targets, showing that cross-reactivity was stable over a
long period of time. The Nef-specific response was
tested on two different occasions (2.3 and 3.1 years of
age) showing cross-reactivity but with a consistently
higher recognition of the A targets compared with the B
targets (Table 2 and data not shown).
Infant EM50 was infected with a subtype F virus. His
Env-, Gag-, Pol-, and Nef-specific CTL responses were
measured on four occasions from age 10.4 to 14.8 years.
Despite variations in the intensity of the specific lysis, the
Pol-specific activity was found to be consistently positive
to the B- but negative to the A-expressing targets (Fig.
2A). In contrast, the Nef-specific activities were detected
consistently to the A but only occasionally to the B
targets (Fig. 2B). The Gag-specific activities were de-
tected over time with varying intensity but with a consis-
tent cross-reactivity to both A and B targets (Fig. 2C).
Env-specific responses were not detected (not shown).
Thus in these two examples of longitudinal follow-up
of CTL activities, cross-reactivity to both B and A targets
was stable for several years. Furthermore, for one of
these individuals, the CTL response was multispecific
and the pattern of clade recognition differed between
different proteins.
DISCUSSION
We studied the extent of cross-reacting CTL activities
from 24 infants infected with HIV-1. Fifteen infants were
infected with a subtype B virus, and nine were infected
with a non-B-subtype virus. For most infants with a pos-
itive CTL response, there was a significant cross-reac-
tivity of CTL between clade B and non-B subtypes. The
cross-clade CTL responses were found in 88%, 83%,
67%, and 55% of infants with a positive CTL responses to
the Pol, Nef, Gag, and Env proteins, respectively. Cross-
reactive CTLs were found in both HIV-1 clade B- and
non-B-infected children.
The typing of HIV-1 strain was performed with the
heteroduplex mobility assay or phylogenetic analysis.
Most children (nine) infected with a clade B virus were
from Europe, where the clade B subtype is prevalent
(Workshop Report from the European Commission and
UNAIDS, 1997). The other six infants infected with a
clade B virus were from North Africa, Africa, Asia, and
TABLE 2
CTL Reactivities of in Vitro Activated PBMC from Infants Infected
with B or Non-B Clade of HIV-1
CTL reactivity
gag pol nef env
B clade
EM 42 Neg B $ A Neg Neg
EM 45 B A 5 B Neg Neg
EM 47 A 5 B A 5 B Neg A 5 B
EM 48 A 5 B A 5 B A 5 B B
EM 54 Neg A 5 B Neg A 5 B
EM 60 Neg A 5 B Neg Neg
EM 64 Neg A 5 B Neg A 5 B
EM 65 Neg Neg Neg B
EM 68 Neg A 5 B Neg A 5 B
EM 75 Neg B Neg Neg
EM 76 A 5 B A 5 B Neg B
EM 78 Neg nt Neg B
EM 84 B A 5 B Neg Neg
EM 89 Neg Neg Neg Neg
EM 96 A Neg Neg Neg
Non-B clade
EM 7 A 5 B A 5 B A $ B Neg
EM 17 B $ A A 5 B A 5 B A 5 B
EM 50 A 5 B B A Neg
EM 59 Neg nt Neg nt
EM 66 Neg A 5 B Neg Neg
EM 79 Neg Neg Neg Neg
EM 95 Neg A 5 B A $ B Neg
EM 97 Neg A 5 B A 5 B Neg
EM 103 Neg Neg Neg Neg
Note. nt indicates not tested; Neg, absence of CTL activity; A, reac-
tivity directed only to the A clade; B, reactivity directed only to the B
clade; A 5 B, reactivity to both A and B clades; A $ B, reactivity to both
A and B clades, with a higher specific lysis to A; and B $ A, reactivity
to both A and B clades, with a higher specific lysis to B.
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Haiti, where this viral subtype has been described. A
total of nine infants were infected with non-B virus. Two
(EM50 and EM66) were infected by blood transfusion
with an F-subtype virus. Child EM50, who was born to an
African mother, was infected in Congo, where this sub-
type is present (Jansens et al., 1997), and child EM66,
who was born to a European mother, was infected in
Romania. Infection of children by clade F virus after
blood transfusion in Romania has been previously re-
ported (Dumitrescu et al., 1994). The seven remaining
children, who were infected with a clade A, D, or G virus,
were born to mothers from sub-Saharan Africa, where
these clades have been frequently described (Janssens
et al., 1997).
Six of the nine infants infected with a non-B virus
developed CTL activities to one or more of the four
proteins tested from a clade A virus. In all infants in
whom there was a positive CTL response, cross-recog-
nition of at least one of the viral proteins tested from a
clade B virus was also observed (EM7, EM17, EM50,
EM66, EM95, and EM97). Infant EM7 was infected with a
clade A virus by perinatal transmission. His Gag-specific
CTL lines were repeatedly cross-reactive to both B and A
targets over time (7 years), and the Nef-specific CTL
FIG. 1. Longitudinal analysis of clade A- and B-specific CTL activities from infant EM7. Gag-specific CTL activities of T cell lines derived from in
vitro activated PBMCs measured at different effector-to-target (E/T) ratios, from age 2.3 to 9.3 years. Targets were autologous B-EBV targets infected
with recombinant vaccinia virus encoding for the Gag gene of clade A (f) or B (M) isolate or with a control vaccinia virus (p).
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activity was predominantly directed to clade A protein. In
a few cases, such as EM7 and EM95 for Nef, EM 17 for
Gag, and EM42 for Pol, CTL activities were directed to
both A and B subtypes but with a consistently higher
lysis to one subtype (Table 2). This suggests the pres-
ence of cross-clade and type-specific CTL responses at
the same time. Infant EM50 was infected by transfusion
with an F-subtype isolate. His pattern of CTL recognition
was remarkably stable over time: the Gag proteins from
the A and B subtypes were recognized equally well, but
the Nef- and Pol-specific CTL activities were directed to
the A and B subtypes, respectively. These data from child
EM50 provide an example, in the same individual, of
different patterns of reactivities: (1) absence of envelope-
specific activities, (2) cross-reactive Gag-specific activity,
and (3) B or A type-specific activities to the Pol or Nef
protein, respectively.
Fourteen of the 15 infants infected with a clade B virus
had CTL activities directed to at least one of the four
proteins tested. As in the case of non-B-infected infants,
most cytotoxic activities were cross-reactive to both
clade A and B proteins: one of one Nef-, 10 of 10 Pol-, four
of eight Env-, and three of the six Gag-specific responses
were directed to both clade A and B proteins.
A number of T cell epitopes have been reported in the
highly conserved Pol and Gag proteins. In view of the
great homology of the Pol and Gag amino acid se-
quences expressed in the recombinant vaccinia vectors
(91.9% and 94% amino acid identity for Pol and Gag,
respectively, between clade ACAR3253 and clade BLAI vi-
rus), the presence of cross-reactive CTL is not surpris-
ing. The comparison of the Nef amino acid sequences
from these two viral isolates (clade ACAR3253 and clade
BLAI virus) reveals 79.5% amino acid identity. However,
most CTL epitopes have been described in the highly
conserved central region (amino acids 63–146, with 86%
amino acid identity) of the Nef protein (Rivie`re et al., 1994
for review), and it is likely that this central region is the
FIG. 2. Longitudinal analysis of clade A- and B-specific CTL activities from infant EM50. Percentage-specific lysis of T cell lines derived from in vitro
activated PBMCs at 10.4, 11.6, 13.2, and 14.8 years of age. CTL activities were measured at different effector-to-target (E/T) ratios against autologous
B-EBV targets infected with recombinant vaccinia virus encoding for the Pol (triangles, Fig. 2A), Nef (circles, Fig. 2B), or Gag (squares, Fig. 2C) genes
of clade A (, F, and f) or B (, E, and M) isolate or with a control vaccinia virus (p).
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target of the cross-reactive CTL responses detected in
the majority of the children with a positive Nef-specific
CTL response.
The type-specific CTL responses (Gag specific for
infants EM45, EM84, and EM96; Pol specific for infants
EM50 and EM75; Nef specific for EM50; and Env specific
for EM48, EM65, EM76, and EM78) are probably directed
to epitopes located in nonconserved regions of the pro-
teins.
Within the 15 clade B virus-infected infants, eight had
detectable envelope-specific CTL activities: four cross-
reactive and four type specific. Of the eight infants in-
fected with non-B-subtype virus (A, D, F, or G) and tested
for envelope-specific activities, only one (EM17) had de-
tectable CTL activities, cross-reactive to both A and B
targets. CTL responses directed to the envelope glyco-
protein were more frequently detected in infants infected
with B-subtype virus compared with infants infected with
non-B-subtype virus, probably reflecting the viral diver-
sity between each subtype (30% nucleotide divergence
in the env gene).
Differences in allele and haplotype frequencies for
HLA has been reported between Caucasians and Afri-
cans. For example, allelic frequency for HLA-A2 is 21.3%
and 13.8% in the populations of France and Zaı¨re, re-
spectively (Imanishi et al., 1991). HLA molecules deter-
mine the viral peptides presented to CTL and may affect
the pattern of CTL recognition. In this study, both sub-
Saharan African and European infants present a high
degree of CTL cross-clade reactivity for Pol, Nef, and
Gag. Thus differences in HLA do not influence HIV-
specific CTL cross-reactivity at the level of protein rec-
ognition, at least in this group of patients.
CTL cross-reactivity among HIV-1 clades was initially
reported in adult volunteers immunized with an HIV-1
clade B-based canarypox vector vaccine (Ferrari et al.,
1997). CTL clones derived from clade B-infected adults in
the United States were shown to be cross-reactive to a B
virus and at least to one non-B clade virus (Cao et al.,
1997). In the same study, CTL lines from 14 Senegalese
adults infected with a non-B clade virus were able to
recognize at least one of the clade B proteins tested.
Similar results were reported in a study of Zambians
individuals: six of the eight subjects infected with a clade
C virus elicited CTL activities specific for the clade B
proteins (Betts et al., 1997). Frequent cross-clade reac-
tivities in the CTL responses were also reported from six
Africans from the Central African Republic infected with
clade A virus and from eight Caucasians infected with a
clade B virus (Durali et al., 1998). In Ugandan patients
FIG. 2—Continued
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infected with non-B clade virus, the cross-clade recog-
nition of the Gag protein by CTL was shown against four
different subtype viruses (McAdams et al., 1998). Most of
the children studied in this work were born to infected
mothers, and thus the HIV-1 subtype diversity reflects the
migration of the parents from Africa (Simon et al., 1996).
This study provides the first example of cross-clade CTL
activity in a sample of infants living in France and in-
fected with B- and non-B-subtype virus, and as in previ-
ous studies, we found a predominance of the CTL cross-
clade reactivity.
Elicitation of CTL reactivities capable of elimination of
virus-infected cells is an important goal for the develop-
ment of an efficient AIDS vaccine. In HIV-1-infected in-
fants, the significant cross-reactivity of CTL between
clade B and non-B viral proteins supports the concept
that vaccines developed based on a single-clade im-
munogen may be applicable to induce broadly reactive T
cell responses, but such a vaccine should include large
sequences containing several epitopes to improve the
probability of cross-reactivity between the vaccine strain
and the field isolate.
MATERIALS AND METHODS
Patients
The children studied were followed at the De´parte-
ment de Pe´diatrie, Hoˆpital Necker (Paris, France). The
legal guardians gave informed consent before their in-
fants entered the study. Most children were born to
HIV-1-infected mothers. Three children, one from Roma-
nia (EM66), one from Africa (EM50), and one from Asia
(EM76), were infected by blood transfusion before 5
years of age. The diagnosis of HIV infection was based
on HIV isolation from PBMCs in the first months of life or
on the presence of anti-HIV antibodies in the serum at 18
months of age. The clinical status of the children was
recorded according to the 1994 revised pediatric classi-
fication system (Centers for Disease Control and Preven-
tion, 1994). HLA genotyping was performed in the De-
partment of Immunology at the Chelsea and Westminster
Hospital (London, UK) using amplification-refractory mu-
tation system PCR (Krausa et al., 1995). These infants
were included in the longitudinal follow-up of HIV-spe-
FIG. 2—Continued
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cific cytotoxic activities at Institut Pasteur (Buseyne et al.,
1993).
Cytotoxic assay
Target cells. For each patient, an autologous Epstein–
Barr Virus (EBV)-transformed B cell line was obtained by
infection of PBMCs with supernatant from the EBV-pro-
ducing cell line B95–8 (American Type Culture Collection
CRL 1612). EBV-B cells (3 3 106 cells) were infected with
the wildtype vaccinia virus or with the various recombi-
nant vaccinia viruses (rvv), at a multiplicity of infection of
10 PFU/cell, for 1 h at 37°C and then washed and
cultured for 16 h at 37°C in 5% CO2 before use in the
cytotoxic assays.
Viruses. All the vaccinia viruses used in this study
were provided by Transge`ne (Strasbourg, France). The
parental virus was the Copenhagen strain of wildtype
vaccinia virus (vv-WT). Foreign genes were inserted un-
der the control of the 7.5-kb vaccinia virus promoter,
inside the thymidine-kinase gene. Recombinant vaccinia
viruses vvTG1139, vvTG1144, vvTG1147, and vvTG3167
encode the Env, Gag, Nef, or Pol protein of HIV-1LAI,
respectively (Buseyne et al., 1993; Rivie`re et al., 1989),
vvTG6059 encodes the Env protein of a clade A isolate
HIV-192CAR3253, and vvTG6026, vvTG6015, and vvTG6052
encode the Gag, Nef, or Pol protein of a clade A isolate
HIV-192UG037, respectively (Durali et al., 1998).
Effector cells. PMBCs were isolated from heparinized
blood by density gradient centrifugation on Ficoll–Me-
trizoate (Ficoll-Paque, Pharmacia, Les Ulis, France). The
generation of CTL lines was performed after in vitro
activation of PBMCs with phytohemagglutinin A (PHA-p,
5 mg/ml) in RPMI 1640 medium (Bioproducts, reference
M12.167.F, Gagny, France) supplemented with 5% human
AB serum (ETS, Bobigny, France), L-glutamine (2 mM,
GIBCO reference 043–05030H, Cergy Pontoise, France),
sodium pyruvate (1 mM, GIBCO reference 043–01360 H),
and nonessential amino acids (13; GIBCO reference
043–01140H), and recombinant human interleukin-2 (100
IU/ml, a generous gift from D. Lando, Roussel Uclaf,
Romainville, France). The cultures were fed every 3–5
days for 3–5 weeks. The cytolytic activity of the T cell
lines was evaluated from day 20 to day 35 after in vitro
stimulation.
Chromium release assays. Cytotoxic assays were
conventional 4-h 51Cr release assays as previously
described (Rivie`re et al., 1989). Briefly, 1 3 106 target
cells were labeled for 1 h with 3.7 MBq of Na2
51Cr04
(reference NEZ030, NEN, Le Blanc Mesnil, France),
washed three times, and distributed at 5 3 103 cells/
well in 0.1 ml of medium in round-bottomed 96-well
microtiter plates (Costar, OSI, Maurepas, France). Var-
ious concentrations of effector cells in 0.1 ml (in trip-
licate or quadruplicate) were added. The plates were
incubated at 37°C in 5% CO2 for 4 h and then centri-
fuged at 150 3 g for 5 min. Supernatant (50 ml) from
each well was transferred with 100 ml of scintillation
liquid (Optiphase Hisafe 3, EGG, Evry, France) into a
96-well harvesting plate (reference 81150401; EGG,
Evry, France), and the radioactivity was measured in a
beta counter (Microbeta 1450, EGG). Percent specific
lysis was calculated as 100 3 (experimental release 2
spontaneous release)/(maximal release 2 spontane-
ous release). Maximal release was obtained from tar-
gets lysed by 5% Triton X-100/1% SDS. Spontaneous
release was obtained from targets incubated 4 h in
medium alone. Assays in which spontaneous 51Cr re-
lease exceeded 35% were discarded. The CTL re-
sponses against HIV antigens were considered posi-
tive if they exceeded the mean of vv-WT-specific lysis
by 3 SDs and by 10% for $1 effector-to-target ratio.
Similarly, clade A-specific CTL response was consid-
ered higher than the clade B-specific CTL response if
it exceeded the mean of vv-B-specific lysis by 3 SDs
and by 10% for $1 effector-to-target ratio, and vice
versa.
PCR, heteroduplex mobility assay (HMA), and
sequence determination
DNA was extracted from PHA-activated PBMCs. Env
fragments were amplified by nested PCR using ED3/
ED12 as outer primers and ES7/ES8 as inner primers
(Delwart et al., 1993). For the HMA, reference plasmids
for each subtype (A–H) were also amplified with inner
primers. Heteroduplexes were analyzed as previously
described (Delwart et al., 1993). For sequence determi-
nation, amplified PCR fragments were purified with a
PCR product purification kit and sequenced by using dye
terminator chemistry (Perkin-Elmer) on an automated
DNA sequencer 373A.
Sequence analysis
Sequences were aligned with the multiple sequence
analysis program CLUSTAL W with minor adjustments.
Reference strains for each subtype for the region ana-
lyzed were included in this study. For construction of the
trees, the pairwise evolutionary distances were esti-
mated by using Kimura’s two-parameter method. Trees
were constructed by a distance-based method, neighbor
joining, and a character-based method, maximum parsi-
mony. These methods were implemented using the
Phylip package (Felsenstein, 1993).
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